Introduction
Thrombotic microangiopathy (TMA) is a clinical condition resulting from severe endothelial damage and leading to microangiopathic hemolytic anemia, consumptive thrombocytopenia, and ischemia of distal organs. 1 TMA is classified into primary forms like hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), secondary forms, which accompany medication use and diseases, and atypical hemolytic uremic syndrome (aHUS), developing due to a defect in the complement system. The incidence of de novo TMA is 2/100,000 cases/year. 2 TMA does not only develop in the native kidney but also appears as a recurrent or de novo condition in the transplanted kidney. The rate of recurrent TMA due to HUS is 4-60% and the rate of de novo TMA is 0.8%. 3 Etiology of de novo TMA includes renal ischemia, antibodymediated rejection, malignancies, viral infections (CMV, influenza A, parvovirus B19, BK polyomavirus, HIV, and HHV-6), antiphospholipid antibodies, anticardiolipin antibodies developing in HCV-positive patients, and medications (calcineurin inhibitors, m-TOR inhibitors, and antiviral medications). 4 In this report, we present our experiences of successful treatment of a renal transplant case of TMA due to BK virus, not a frequent cause of TMA.
Case report
A 41-year-old woman undergoing renal transplantation from a living donor nine months ago presented to our outpatient clinic for her monthly screening. On physical examination, her i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 5 5 - blood pressure was 130/80 mmHg, her heart rate was 78/min, her respiratory rate was 16/min, and she had no pathological signs. On history taking, it was found that the patient underwent hemodialysis for end-stage renal failure due to lupus nephritis for four years, had renal transplantation nine months ago, and was on prednisolone 5 mg/day, tacrolimus 2.5 mg/day, azathioprine 100 mg/day, acetylsalicylic acid 100 mg/day, omeprazole 40 mg/day, and amlodipine 10 mg/day. Results of the laboratory investigations were as follows: hemoglobin: 10 g/dl, Htc: 29.6%, MCV: 120 fl, white cell count: 3400/mm 3 (neutrophil: 68%, lymphocyte: 22%, monocyte: 9%, eosinophil: 1%), thrombocyte count: 64,000/mm 3 , urea: 73 mg/dl, creatinine: 1.9 mg/dl, K: 4.0 mEq/l, Na: 140 mEq/l, LDH: 312 U/l, direct bilirubin: 2.5 mg/dl, indirect bilirubin: 2 mg/dl, AST: 32 U/l, ALT: 35 U/l, Ca: 9.2 mg/dl, albumin: 4.3 g/dl, and CRP: 3 mg/dl. Results of complete urine analysis were as in the following: pH: 6.5, density: 1009, protein: +, white cell count: 1/High power field (HPF), and red cell count: 1/HPF. Urine culture did not isolate any microorganisms. Twenty-four hour urine specimens had protein of 254 mg/day. The patient, who had basal creatinine of 1.3 mg/dl, was admitted to our clinic to determine etiology of her renal dysfunction and pancytopenia and to treat these conditions. Since the patient had thrombocytopenia and high LDH levels, peripheral blood filming was performed, which showed schistocytes. Direct and indirect Coombs tests did not reveal hemolysis, serum haptoglobulin was low (<5.83), and reticulocytosis was present (3.79%). PT, aPTT, INR, B12, and folic acid levels were normal. Abdominal ultrasonography and graft Doppler ultrasonography demonstrated no pathologies. Serum C3 and C4 were normal and anti dsDNA, ANA, lupus anticoagulant, and antiphospholipid antibodies were negative. Parvovirus, B19, Hbs Ag, Anti-HIV, Anti-HCV, and CMV PCR tests, performed to determine possible etiologies of infections, did not show any pathogens. Serum BK virus PCR levels were 3.8 Â 10 4 . ADAMTS13 activity, indicative of TTP, was 48.5% (40-130%). Specimens for mutation analysis were obtained to determine aHUS. The patient was suspected of having BKV nephropathy, TMA, and acute rejection and a renal graft biopsy was planned. However, renal biopsy could not be performed since the patient had thrombocytopenia. Due to suppression of the bone marrow and BKV positivity, the dose of azathioprine was first reduced and then the drug was discontinued. During follow-up of the patient, thrombocyte count decreased to 54,000 and creatinine increased to 2.29 mg/dl. Serum tacrolimus level was found to be 5.7 ng/ml. Since the clinical picture was likely to be triggered by tacrolimus, it was discontinued on the third day of treatment. Since biopsy could not be performed, acute rejection could not be excluded. Therefore, empirical treatment with intravenous pulse steroid, plasmapheresis, and IVIG were planned. The patient was given intravenous pulse steroid 250 mg/day for three days, followed by prednisolon 60 mg/day through oral route. She was administered plasmapheresis six times, followed by IVIG 15 g. On the tenth day of treatment, thrombocyte count was 120,000, creatinine was 1.33 mg/dl, and indirect bilirubin and LDH levels were normal. Renal biopsy demonstrated normal morphological features under glomerular light microscopy ( Fig. 1) . Very little interstitial and focal inflammatory cell infiltrations were observed. Tubulitis was rare and mild (1-2 lymphocytes/tubule). Typical nuclear BKV inclusions were detected in a few tubules in the medulla (Fig. 1 ). Staining with SV40 was also positive for the inclusions (Fig. 2) . Staining for C4d was negative. Upon improvement of renal functions in a very short time and improvement of the hematological picture, the dose of steroid was reduced and triple immunosuppressive therapy was planned. First, tacrolimus was initiated. When HUS activation was not observed, microphenolate sodium (720 mg/day) was started. Fifteen days later, BKV PCR was 1.8 Â 10 4 . After the dose of tacrolimus was adjusted to 4-5 ng/ml and the patient was instructed to continue her triple immunosuppressive therapy, she was discharged. One month after her discharge, BKV PCR was negative. TMA did not recur during four-month follow-up and clinical and biochemical tests yielded normal results. i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 5 5 -1 5 8 3.
Discussion
De novo TMA development has rarely been reported in the literature and it is more frequent within three months of transplantation. It appears in renal transplant recipients commonly due to immunosuppressive medications (calcineurin inhibitors, mTOR inhibitors, and OKT-3). 3, 4 The case present here had de novo TMA due to BK virus, a rare cause of TMA, nine months after transplantation. The patient was examined to determine whether she had primary or secondary aHUS. She did not have history of bloody diarrhea, which is considered indicative of primary HUS. Examination for Shiga toxin-producing Escherichia coli was not needed. Absence of fever and neurological signs and presence of normal ADAMTS 13 activity excluded TPA. Signs of secondary HUS including lupus activation, malignant hypertension, influenza, and streptococcal infection were not detected. Tests for hepatitis markers, anti-HIV, and parvovirus B 19 were negative. Serum BK viral load was found to be 3.8 Â 10 4 copies/ml. Another condition the patient likely to have was atypical uremic syndrome (aHUS). aHUS results from mutations of complements. About 50% of the patients with a HUS have been reported to have mutations of factor H, serine protease factor 1, and membrane cofactor protein. 5 Fifty percent of the patients suffering from aHUS attacks progress into ESRF. Rates of recurrences after transplantation reach 80%. 6 It has been reported in the literature that plasmapheresis alone was not sufficient to treat cases of recurrent aHUS due to mutations of the complements and that specific treatment should be given to inhibit inappropriate activation of the complements. 7 Lack of familial history of aHUS, development of TMA in the ninth month of transplantation, unprogressive nature of the disease, rapid responsiveness to plasmapheresis, and lack of a recurrence of TMA during three-month follow-up excluded the diagnosis of aHUS. TMA, likely to be triggered by acute humoral rejection, tacrolimus use, and BK virus nephropathy, was suspected. TMA due to tacrolimus use is encountered early after transplantation and in fact frequently appears within three months of transplantation. 8 Despite this information, tacrolimus was discontinued in case it triggered the clinical picture. To make the differential diagnosis of all these conditions, renal biopsy was needed. However, it could not be performed due to thrombocytopenia. Since acute humoral rejection was likely to induce the clinical picture and creatinine levels continued to increase, empirical pulse steroid was initiated. Plasmapheresis was performed to treat both acute rejection and TMA. In addition, IVIG was initiated. Twelve days later, when thrombocyte count increased, renal biopsy was performed, but no histological findings indicative of TMA or acute rejection were found. Laboratory and histological signs might have improved thanks to treatments administered. However, renal graft biopsy proved the presence of BK virus. As a result, underlying etiology of TMA in this case turned out to be BK virus nephropathy. The biopsy showed nuclear BKV inclusions in a few tubules and staining with SV40 was positive for BK virus. There have been three reports about transplant recipients with BK virus-related vasculopathy in the literature. One of these reports was about a renal transplant recipient. Another report was about a bone marrow transplant recipient. 9, 10 During their follow-up, these patients developed TMA and were found to have BK virus. The third report was about two renal transplant recipients having BK virus nephropathy. They developed the clinical picture of TMA after IVIG was given, which was incriminated for etiology of TMA. 11 However, the authors referred to aforementioned two cases and suggested that BK virus could also be responsible for the etiology. The factor triggering TMA in all abovementioned conditions is endothelial damage. 12 Several clinical pictures of TMA related to many viruses such as HIV, hepatitis C, herpes viruses, CMV, EBV, parvovirus B19, etc. in addition to BK virus have been reported. 13 Although the mechanism of the pathophysiology in these conditions has not been well understood, direct endothelial damage has been thought to play a role. Genetic factors and several underlying conditions may cause clinical manifestations.
Early diagnosis and treatment of TMA can be lifesaving. In the present case, the clinical picture of de novo TMA improved after administration of plasmapheresis and IVG. The patient was not found to have any pathology likely to cause TMA except for BK virus vasculopathy.
